The capacities of norfloxacin (MK-0366) and neomycin to reduce the numbers of bacteria in the gastrointestinal tracts of rats were evaluated. Results of a 3-day treatment with norfloxacin were compared with those of a 3-day treatment with neomycin. Both drugs significantly decreased gram-negative and gram-positive bacteria. Norfloxacin effected a significantly greater reduction in numbers of gram-negative bacteria than did neomycin. Norfloxacin also significantly increased the number of anaerobic bacteria. Although neomycin reduced grampositive bacteria more effectively than did norfloxacin, this difference between the two drugs was not significant. Norfloxacin merits further study for potential as a bowel sterilant.
spectrum and potency seem far superior to those of other members of this chemical class (i.e., oxolinic, nalidixic, and pipemidic acids and cinoxacin) (3) (4) (5) . In vitro, norfloxacin is highly active against most enterobacteria, including Pseudomonas species, somewhat less active against gram-positive species (7) , and relatively inactive against anaerobic bacteria (7, 9) . Preliminary studies indicate that norfloxacin can be used to treat urinary tract infections (8) . In addition, its antibacterial spectrum makes it potentially useful for treatment of many enteric infections (11). To further evaluate t,he in vivo activity of norfloxacin on enterobacteria, we compared the efficacies of norfloxacin and neomycin against the aerobic flora of the gastrointestinal tract in a rat model.
MATERIALS AND METHODS
Thirty-nine Sprague-Dawley rats (King Animal Laboratories) were distributed into three groups. All animals were fasted for 1 Stool samples were obtained 1 day before the start of the study. At autopsy, samples were obtained from the lumens of the distal esophagus (blank paper disks), ileum, cecum, midcolon, distal colon, and rectum. Biopsies for bioassay of test drug were taken from the same locations except the rectum. Blood samples were drawn. Lumenal content samples were divided for culturing and bioassay. Samples for culture were immediately put into thioglycolate to prevent oxidation. Gram-negative bacteria were grown aerobically on MacConkey agar. Gram-positive bacteria were cultured on azide agar with 5% sheep blood. Tenfold dilutions of from 102 to 106 were plated, and the cultures were incubated ovemight at 37°C. Anaerobic bacteria, cultured on brain-heart infusion agar with 5% sheep blood plus vitamin K-hemin, were incubated at 37°C overnight in GasPak jars (BBL Microbiology Systems). The numbers of CFUs per gram in lumenal specimens were estimated for each type of bacteria.
Both norfloxacin and neomycin concentrations were determined by a disk diffusion method. Klebsiella pneumoniae ATCC 10031 grown on nutrient agar plus 2% yeast extract was used for norfloxacin. Staphylococcus aureus ATCC 6538 P grown on nutrient ggar was used for neomycin. Bowel specimens were flushed for one minute with saline and then homogenized with phosphate buffer at pH 7.0 for norfloxacin and at p1 8.0 for neomycin. Serum was examined undiluted. Identical zone sizes were found with identical concentrations of norfloxacin in serum and buffer which indicated that serum had no influence on the bioassay. Further recovery studies were not performed. Only concentrations greater than 1 ,ug/g could be detected with the bioassay. RESULTS
The number of animals, median weight, median total fluid intake, and median total drug intake are shown in Table 1 . Norfloxacin and Table 3 . There were relatively large inter-and intragroup differences. However, using the Kruskal-Wallis one-way analysis of variance (12), the variation among the groups was not statistically significant concerning pretreatment numbers of gram-negative (P < 0.90), grampositive (P < 0.40), or anaerobic bacteria (P < 0.20).
Within each individual group, both norfloxacin and neomycin significantly reduced (P < 0.05) gram-positive and gram-negative bacteria (Wilcoxon matched-pairs signed-ranks test [12] ). The numbers of gram-positive and gram-negative bacteria in the control group did not change significantly. The number of anaerobic bacteria rose significantly in the norfloxacin-treated group, whereas there were no significant changes in the neomycin-treated or control groups.
Finally, the posttreatment numbers of bacteria in both treatment groups were compared, using the Mann-Whitney u test (12). The number of gram-negative bacteria was significantly lower in the norfloxacin group (P < 0.02). Although gram-positive bacteria were lower in the neomycin group, the difference was not significant (P = 0.19). The number of anaerobic bacteria was significantly higher in the norfloxacin group than in the neomycin group (P = 0.02). DISCUSSION In vitro, norfloxacin has been shown to be more effective than nalidixic acid (9), cinoxacin (9), and aminoglycosides (7) against enterobacteria. Although resistance to nalidixic acid and its derivatives may develop, the apparent absence of transferable resistance in pathogenic gram-negative bacteria is an advantage of these drugs (1). Consequently, we were interested in comparing the in vivo effects of norfloxacin and neomycin on enterobacteria. For preoperative gut sterilization, neomycin is administered in three 1-g doses (2) . We dissolved the drugs in the drinking water of the animals. Drug concentrations were chosen rather arbitrarily, and the total drug intake was about three to four times greater than the usual clinical dosage of neomy- 1 x 10"-3.1 x 109) (1.5 x 106-2.3 x 109) cin. Although a 1-day treatment would have better mimicked the clinical use of neomycin, we undertook a 3-day study because we have found that rats kept in separate cages may take in less fluid than usual. Since-the animals were not randomized among the three groups, the rats in group B weighed more than those in the other groups. Nevertheless, when fluid and drug intake were calculated on a weight basis, there were no differences among the groups.
Norfloxacin was more active against gramnegative bacteria and slightly less active against gram-positive bacteria than was neomycin, although the latter bacteria were significantly reduced in number. These results are not directly applicable to the clinical use of norfloxacin. However, Sleijfer et al. (13) conducted a study in which 110 granulocytopenic patients randomly received either prophylactic treatment with oral drugs (32 of 53 patients received nalidixic acid) or served as controls. The authors attempted a "selective decontamination" of the digestive tract; i.e., aerobic gram-negative bacteria and yeast were suppressed to undetectable concentrations while anaerobic bacteria were left intact, thus preventing colonization of the digestive tract by potentially pathogenic aerobic species. Infections in the treated group were significantly fewer than in the control group. In demonstrating the clinical usage of nalidixic acid against enterobacteria, Sleijfer et al. showed that the need for gut sterilization is not restricted to preparation for colonic surgery. Similarly, gut sterilization with oral antibiotics has been useful in patients with severe burns (6) .
Our study suggests that rats may be used to screen antimicrobial drugs for their capacity to sterilize the bowel. In search of bowel antiseptic agents, Poth used dogs many years ago and eventually discovered succinylsulfanilamide (10). Although postsurgical infections have been dramatically reduced with the advent of antibiotic drugs, even better results may be expected with the many newly developed antimicrobial agents. Since any new antibiotic regimen must be compared, however, with the best existing regimen, as Condon points out (2), a clinical study intended to reveal a reduction of surgical infection rate from the present 5 to 10%o to 2 to 4%o must include about 1,000 patients. Therefore, preliminary studies in an animal model are needed to screen and select drugs to be later tested in a clinical study. 
